DDInter1309 DDInter1658
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Nizatidine {u} (Compound) resembles {v} (Compound) Ranitidine
Nizatidine {u} (Compound) binds {v} (Gene) HRH2
Nizatidine {u} (Compound) upregulates {v} (Gene) RAB27A
Nizatidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Nizatidine {u} (Compound) downregulates {v} (Gene) SLC35B1
Nizatidine {u} (Compound) causes {v} (Side Effect) Sinusitis
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flurbiprofen
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Nizatidine (Compound) resembles Ranitidine (Compound)
Nizatidine (Compound) binds HRH2 (Gene)
Nizatidine (Compound) upregulates RAB27A (Gene)
Nizatidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Nizatidine (Compound) downregulates SLC35B1 (Gene)
Nizatidine (Compound) causes Sinusitis (Side Effect)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib